GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OTCPK:NVZMF) » Definitions » NonCurrent Deferred Liabilities

NVZMF (Novonesis (Novozymes) B) NonCurrent Deferred Liabilities : $0 Mil (As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Novonesis (Novozymes) B NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Novonesis (Novozymes) B's non-current deferred liabilities for the quarter that ended in Jun. 2024 was $0 Mil.

Novonesis (Novozymes) B NonCurrent Deferred Liabilities Historical Data

The historical data trend for Novonesis (Novozymes) B's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B NonCurrent Deferred Liabilities Chart

Novonesis (Novozymes) B Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Novonesis (Novozymes) B Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Novonesis (Novozymes) B NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Novonesis (Novozymes) B Business Description

Address
Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

From GuruFocus

Q3 2021 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2020 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2023 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2020 Novozymes A/S Organic Sales Call Transcript

By GuruFocus Research 02-14-2024

Q4 2021 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2020 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2022 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2023 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Half Year 2024 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 08-29-2024